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tively. DISCUSSION : In absence of head-to-head trials, indirect comparisons can 
provide useful insights to clinicians and reimbursement-decision making on relative 
efficacy of treatments. The probabilistic interpretation of Bayesian results suits these 
purposes, allowing probabilistic statements on which treatment is likely to be the 
most effective. Bayesian probabilities and credible intervals have different interpre-
tation than classical p-values and confidence intervals. Bayesian results fit well in 
decision modelling, as resulting posterior distributions can serve as priors in proba-
bilistic cost-effectiveness modelling. Assumptions behind NMA to generate unbi-
ased results were considered valid for IBR vs IDEL+OFA-comparisons, as included 
patient-populations were nearly identical. Estimates versus PC may be conservative, 
given higher relative treatments effect in more severe patients. ConClusions: 
In absence of direct evidence, NMA-results suggest improved PFS and OS for IBR 
compared to IDEL+OFA and to PC in R/R CLL-patients with high certainty, and can 
serve as input in HTA-decision modelling.
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objeCtives: This study aims to investigate the association of the major molecular 
response (MMR) and complete cytogenetic response (CCyR) as surrogate outcomes 
with overall survival (OS) and progression free survival (PFS) in chronic phase of 
chronic myeloid leukemia (CML-CP) patients using evidence from observational or 
experimental study. Methods: We conducted using existing systematic reviews 
and meta-analysis to quantify the association between CCyR and/or MMR at 12 
months and OS and/or PFS. The overall survival rate or progression free survival rate 
according to the responders or non-responders of MMR or CCyR at 12 months after 
the initiation of first-line TKI therapy (imatinib, dasatinib or nilotinib) was extracted 
by two independent reviewers. A weighted average of the OS and PFS at differ-
ent yearly intervals was estimated respectively for both the responders and non-
responders with assumption of no censoring. The analyses were carried out using 
R package “metafor”. Results: Eleven studies provided data on the association 
between CCyR or MMR and OS or PFS after imatinib treatment however there were 
no such studies about dasatinib or nilotinib treatment. Patients who experience 
CCyR following 12 months’ TKI therapy have better long-term (7 –year) OS and PFS 
(OS 97.0% vs 82.5; PFS 97.0% vs 69.6%) than patients who are non-responders at 12 
months. Patients who experience MMR at 12 months’ TKI therapy have better long-
term (5-year) OS and PFS (OS 99.4% vs 93.4%; PFS: 89.9% vs 85.3%). ConClusions: 
This study identified evidence of the association between CCyR and/or MMR and 
survival among the TKI treated CML-CP patients, and this is based entirely on 
imatinib treatment studies. The evidence of dasatinib and nilotinib is limited by 
the amount and quality of data available. Therefore further research is needed 
whether this relationship between the surrogate outcomes and final outcomes are 
equally applicable to dasatinib and nilotinib.
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COmPArisON Of treAtmeNt durAtiON AmONg tArgeted AgeNts iN 
reNAl Cell CArCiNOmA (rCC)
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objeCtives: Conducting comparative effectiveness research among multiple 
classes of treatments may inform optimal treatment based on the real-world 
effectiveness. We conducted a retrospective analysis comparing the duration of 
six leading treatment options in renal cell carcinoma stratified by line of ther-
apy. Methods: Using claims data (MORE2 Registry), patients with renal cell car-
cinoma who started and completed at least one line of treatment during the study 
period (January 2012 to February 2014) were identified by ICD9 code 189.0. Line 
of therapy (LOT) was assigned based on the patient’s available treatment history. 
Analysis was stratified by LOT. Univariate analysis of variance was performed to 
compare mean durations among treatment options, LOT, and therapeutic class. 
Multivariate analysis controlling for demographic and treatment characteristics 
will be presented in the poster. Results: Patients received 1240 complete lines 
of therapy. Mean duration of treatment by line of therapy was as follows: 1st LOT: 
4.0 mo (n= 599); 2nd LOT: 3.2 mo (n= 357); 3rd LOT 3.1 mo (n= 284). There was sta-
tistically significant difference in mean duration of therapy between the groups of 
patients by second line regimen (p= 0.003). Within the second line patient group 
the tyrosine kinase inhibitor (TKI) treated patients had greater duration compared 
to the mammalian target of rapamycin (mTOR) treated patients (3.5 mo vs 2.6 
mo, p-value= 0.006). However no difference in duration was observed among first 
(p= 0.7239) and third line regimens (p= .0.6476). ConClusions: In this study there 
was statistically significant difference in duration among leading systemic agents 
used for second-line treatment of RCC where patients were shown to remain on 
TKI treatment longer than mTOR treatment. Future research should determine if 
toxicity and costs influence duration in this therapeutic area.
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objeCtives: Understanding prescriber perceptions of efficacy and tolerability 
among available RCC treatments in a real-world population may inform current 
areas of unmet need and provide context for the adoption of new therapeutics. We 
conducted a retrospective analysis evaluating the drug utilization patterns and 
duration of tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin 
(mTOR) inhibitors in patients with newly diagnosed and relapsed RCC. Methods: 
Using claims data (MORE2 Registry), patients with RCC who completed at least one 
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objeCtives: To evaluate the patterns of metachronous metastases in patients with 
breast cancer. Methods: Patients diagnosed with non-metastatic (M0) breast cancer 
at initial diagnosis between 2006-2008 were selected from the Eindhoven Cancer 
Registry, which is a population-based registry and records data on newly diagnosed 
cancer patients. By means of active follow-up, additional data on date of diagnosis 
and localization of metachronous metastases were collected directly from the patient 
files. Anatomical sites of metastasis were registered according to the International 
Classification of Diseases for Oncology (ICD-0). Proportions of metachronous metas-
tases between tumour and treatment characteristics were compared using the Chi2 
test. A p-value < 0.05 was considered significant. Results: There were 1,382 patients 
diagnosed with M0 breast cancer with a mean (±SD) age of 60.3 (±13.8) years. Of those, 
116 patients (8%) developed metachronous metastases during a median (±SD) follow-
up of 4.1 (±1.1) years. The mean (±SD) age at the time of diagnosis of metachronous 
metastases was 61.7 (±14.3) years. Diagnosis of metachronous metastases was con-
firmed by imaging in 76 patients (66%), in 39 patients (34%) by histopathology and 1 
patient (1%) based on clinical symptoms. The most frequent metastatic sites affected 
were bone (29%) and liver (17%). Breast cancer patients who developed metachro-
nous metastases were significantly more often diagnosed with a hormone recep-
tor positive and a HER2-negative tumor, had a poor tumor grade, had a tumor size 
greater than 2.1 cm, and more often received chemotherapy at initial breast cancer 
diagnosis. ConClusions: Of the initially M0 breast cancer patients, 8% developed 
metachronous metastases, of which one-third developed bone metastasis. The risk 
of developing metachronous metastases varies among different characteristics at 
initial breast cancer diagnosis. Identifying the patterns of metachronous metasta-
ses and characteristics increasing the risk for developing metachronous metastases 
contributes to tailored follow-up and adequate initial M0 breast cancer treatment.
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objeCtives: Elderly patients with newly diagnosed multiple myeloma (MM) 
are usually not considered for stem cell transplantation. Treatment alternatives 
include multidrug regimens combining prednisone (P)/dexamethasone (D), tha-
lidomide (T), bortezomib (V), cyclophosphamide (C), and melphalan (M). Head-to-
head comparisons between the different treatments are lacking. We compared 
the effectiveness of different first-line treatment strategies for patients with 
MM (age > 65 years) in terms of progression-free survival (PFS) and overall sur-
vival (OS). Methods: We performed a systematic literature search in MEDLINE, 
EMBASE, Cochrane Library and CRD databases. The primary search yielded 2,673 
citations. Ten randomized controlled trials (RCT), enrolling a total of 3,782 patients, 
were included in our meta-analysis and indirect treatment comparisons. We calcu-
lated pooled hazard ratios (HR) with 95% confidence intervals (95%CI). Results: 
Meta-analysis of six RCTs comparing MPT vs. MP showed a statistically significant 
benefit of MPT in PFS (HR 0.75, 95%CI 0.64-0.88) but no statistically significant dif-
ference in OS (HR 0.90, 95%CI 0.75-1.08). The indirect comparison of MPT vs. MPV 
showed a benefit in PFS for MPV (HR 1.41, 95%CI 1.04-1.90) but no OS difference 
(HR 1.29, 95%CI 0.98-1.70) using MP regimen as the common comparator. There 
was no difference between MPT vs. CTD, indirectly analyzed with MP as common 
comparator (PFS: HR 0.91, 95%CI 0.73-1.14; OS: HR 1.01, 95%CI 0.78-1.32). Indirect 
comparison was also possible for VMPT-VT vs. VTD, both compared to MPV in 
the original RCTs. VMPT-VT showed a statistically significant benefit in PFS (HR 
0.48, 95%CI 0.33-0.71) but no difference in OS (HR 1.04, 95%CI 0.69-1.59) compared 
to VTD. ConClusions: While some regimens showed improved PFS, there was 
no evidence for a benefit in OS comparing the different treatment strategies. 
Combining all treatment strategies based on published data by using a network 
meta-analysis may help to identify the optimal treatment option.
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objeCtives: To assess the relative efficacy of ibrutinib (IBR), a first-in-class BTK- 
inhibitor, versus Idelalisib+ofatumumab (IDEL+OFA) and physician’s choice in 
relapsed/refractory (R/R) CLL-patients using Bayesian Network Meta-Analysis 
(NMA). Methods: Three RCTs in R/R CLL-patients were identified with OFA as 
common treatment arm. IBR (Byrd, 2014) and IDEL+OFA (Jones, 2015) showed 
improved investigator-assessed PFS (HR= 0.13 and 0.27, respectively) and OS 
(HR= 0.39 and 0.74, respectively) versus ofatumumab in R/R CLL-patients. Osterberg 
(2014) compared PFS (INV) (HR= 0.56) and OS (HR= 0.72) for OFA to physician’s 
choice (PC), a mix of well-established CLL-treatments, in more severe patients. A 
Bayesian NMA was conducted in line with NICE guidelines, using a fixed-effect 
model with non-informative priors. Posterior distributions for the HR were sum-
marized by median values and 95% credible intervals. Results: HR for PFS (INV) 
comparing IBR vs IDEL+OFA and PC were 0.49 ([0.28;0.87],P(HR< 1)= 99.2%) and 0.07 
([0.04;0.13],P(HR< 1)= 100%), respectively. HR for OS comparing IBR vs IDEL+OFA and 
PC were 0.52 ([0.24;1.14],P(HR< 1)= 94.7%) and 0.28 ([0.13;0.80],P(HR< 1)= 100%), respec-
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objeCtives: Obesity is associated with an increased risk of breast cancer, and is 
also positively associated with tumor size and a higher probability of having posi-
tive axillary lymph nodes and faster growing tumors. It has been suggested that up 
to 50 % of postmenopausal breast cancers are attributable to obesity. Accordingly, 
this study assessed the impact of lifestyle intervention on body mass index (BMI) 
in women with breast cancer. Methods: This is a randomized clinical trial study 
.The Study samples were 80 women with stage I, II, or III breast cancer, that oper-
ated for breast cancer and their chemotherapy or radiation therapy completed 3-18 
months ago. They are divided randomly into two groups; control group and lifestyle 
interventions group. Those in the lifestyle intervention group were instructed to 
practice aerobic exercises 45-60 minutes three times per week for 24 weeks with 
dietary energy restriction training. Those in the control group were instructed to 
continue normal activities and their routine health care. Data were obtained from 
the patient information form and body mass index form that completed before and 
after the lifestyle intervention in both groups. Results: No baseline differences 
existed between the two groups for the mean of BMI (p = 0.366) before the study 
; but the mean of BMI in the lifestyle intervention group after the intervention 
decreased to 25.12 ± 2.86, while in the control group it increased to 30.42 ± 6.89. The 
difference between the mean of BMI among the two groups after the intervention 
was statistically high (p = < 0.001). ConClusions: Lifestyle intervention could be 
considered as part of a cancer survivorship program. For women with breast cancer, 
lifestyle intervention can decrease body mass index. Additional research in lifestyle 
intervention along with cognitive behavioral therapy also may be beneficial.
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objeCtives: Minimally invasive hysterectomy using the Da Vinci robot-assisted 
surgical system remains uncertain if the technology offers benefits compared with 
traditional laparotomy. The aim of this study was to compare effectiveness and safety 
of robot-assisted laparoscopic hysterectomy (RALH) compared with traditional lapa-
rotomy in endometrial cancer. Methods: We searched potentially relevant studies 
using Ovid-Medline, Ovid-EMBASE, Cochrane library, and 5 local medical databases 
through May 2014. The outcomes were overall complications, peri-operative complica-
tions, post-operative complications and specific morbidities for safety outcomes, sur-
vival, recurrence, length of stay (LOS), estimated blood loss (EBL), operative time (OT) 
for effectiveness outcomes. Two independent reviewers extracted data and assessed 
the risk of bias for non-randomized studies. Results: 19 eligible comparative studies 
representing 3,062 patients were identified. Overall and disease-free survival didn’t 
results in significant difference for 1 study. Pooled mean difference for resected total 
lymph nodes (LNs), pelvic LNs and aortic LNs showed no significant difference (WMD 
1.59, 95% CI -1.64-4.83, I2= 90%; WMD -1.64, 95% CI -4.21-0.94, I2= 91%; WMD 0.96, 95% 
CI -1.30-3.23, I2= 93%, respectively). LOS and OT was shorter for RALH (WMD -2.85, 
95% CI -3.28, -2.41, I2= 91%; WMD 44.15, 95% CI 20.91, 67.39, I2= 98%, respectively). 
EBL was significantly reduced in RALH group (WMD -159.62, 95% CI -189.73, -129.50, 
I2= 83%). Overall, intra-operative and post-operative complications (RR 0.37, 95% CI 
0.28-0.49, I2= 9%; RR 0.40, 95% CI 0.23-0.72, I2= 0%; RR 0.49, 95% CI 0.36-0.68, I2= 0%, 
respectively); the incidence of wound infection, wound dehiscence, wound com-
plications, ileus or bowel obstruction, infection, readmission, ICU stay, transfusion 
were significantly fewer but vaginal cuff dehiscence or separation were significantly 
higher in RALH than in laparotomy. Other individual peri-operative complications 
were similar. ConClusions: RALH may be a generally safer and better option than 
laparotomy in endometrial cancer. Robotic surgery is associated with shorter LOS, 
OT; lower EBL and fewer complications than laparotomy. Further prospective studies 
with long term follow-up are required.
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objeCtives: Patients with recurrent or metastatic SCCHN, particularly those with 
platinum-refractory disease, face limited treatment options that demonstrate dif-
ferentiated survival advantages and maintain or improve QoL. This study summa-
rized outcomes from systematically identified clinical studies reporting OS or QoL 
among patients with recurrent or metastatic SCCHN. Methods: Eligible English-
language publications (01/2005–10/2014) were identified using EMBASE, MEDLINE, 
and the Cochrane Library. Results: Thirty-eight publications reporting clinical 
outcomes from 35 studies in all lines of therapy were identified (5902 patients). 
Most study arms received chemotherapy-based combinations. When stratified 
by prior treatment, median OS ranged from 7.4–11.1 months for platinum-naïve 
patients (11 arms), 4.3–11.8 months for platinum-refractory patients (12 arms), and 
5.0–32.2 months for patients with unspecified or mixed platinum history (38 arms). 
When stratified by current treatment regimen component, median OS ranged from 
4.3–12.4 months for cetuximab, 5.0–32.2 months for docetaxel, 5.2–6.7 months 
for methotrexate, and 4.3–19.1 months for paclitaxel. Among platinum-refractory 
patients, median OS ranged from 4.3–11.8 months for cetuximab, was 6.7 months 
for docetaxel and 5.2 months for methotrexate, and ranged from 4.3–11.7 months 
for paclitaxel. Fifteen studies reported QoL outcomes, including general-cancer 
and head-and-neck-specific QoL with impairments observed in domains includ-
ing eating, speech, appearance, and social impacts. Improvements, especially in 
pain, swallowing, and speech, were observed among platinum-naïve patients. 
However, among platinum-refractory patients, no statistically significant impacts 
on QoL were attributable to regimens including cetuximab or methotrexate, and 
no studies were identified reporting QoL outcomes with docetaxel or paclitaxel. 
line of treatment with a TKI (sunitinib, pazopanib, axitinib, or sorafenib) and/or 
mTOR inhibitor (everolimus or temsirolimus) during the study period (January 2012 
to February 2014) were identified by ICD9 code. Descriptive statistics were used to 
evaluate patterns of care in the overall sample. Univariate analysis was conducted to 
compare individual treatments. Multivariate analysis controlling for covariates will 
be shown in the poster. Results: 917 RCC patients meeting the study criteria were 
identified. Sunitinb (34%) was the most widely used drug followed by pazopanib 
(23%) and axitinib (14%). Mean duration of TKIs (3.7 mo) were higher than the mTOR 
(2.92) inhibitors (p= 0.004): sunitinib (3.87), pazopanib (3.67), axitinib (3.52), sorafenib 
(3.46), everolimus (3.12), and temsirolimus (2.58). Based on the univariate analysis 
there was statistically significant (p= 0.0054) but not clinically meaningful differ-
ence in duration across the individual treatments. ConClusions: Real-world data 
analysis demonstrates significantly shorter duration of therapy of TKI and mTOR 
inhibitors than is published in clinical trials (range 4-8 months). Study results sug-
gest an unmet treatment need for RCC despite the rapid expansion of the number 
of drugs with an RCC indication in the past 5 years.
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objeCtives: Approved treatment options for patients with recurrent GBM yield 
limited survival and QoL benefits. A systematic review was conducted to sum-
marize OS, QoL, and NF among patients with recurrent GBM. Methods: Eligible 
English-language publications (01/2005–10/2014) were identified using EMBASE, 
MEDLINE, and the Cochrane Library. Results: Fifty publications were identified. 
Among bevacizumab-naïve patients treated with monotherapies, median OS ranged 
from 6.4–9.3 months with initial bevacizumab treatment, 6.6–9.4 months with other 
targeted therapies (enzastaurin, cediranib, and sunitinib), 7.1–11.7 months with 
chemotherapies (lomustine, verubulin, and temozolomide), and 10.9–11.4 months 
with the anti-hepatocyte growth factor monoclonal antibody rilotumumab. Among 
those treated with combination therapies, median OS ranged from 8.7–16.0 months 
with bevacizumab + chemotherapy, 5.6 months with bevacizumab + sorafenib, and 
9.4 months with cediranib + lomustine. Among patients with prior bevacizumab 
treatment, median OS was 3.4 months with verubulin, 4.4 months with sunitinib, 
and 3.4–3.6 months with rilotumumab. Among studies not specifically reporting 
outcomes for bevacizumab-naïve or -experienced patients, median OS ranged 
from 4.4 months with temsirolimus to 24.5 months with fotemustine. Factors that 
paralleled longer OS included male sex, younger age, fewer prior therapies, faster 
brain tissue diffusion on imaging, longer time to recurrence, smaller tumor volume, 
better performance status, and methylated O6-methylguanine-DNA methyltrans-
ferase promoter regions. Eight studies assessed the humanistic burden on patients. 
Baseline QoL and NF among these patients were worse compared with both the 
general population and patients with other cancers. No studies reported treatment-
related improvements in QoL or NF. ConClusions: Currently available therapies 
for recurrent GBM are associated with limited OS duration and a lack of improve-
ments in QoL or NF. Among bevacizumab-naïve patients, initiation of bevacizumab 
or other mono- or combination therapies resulted in median OS less than 1.4 years, 
indicating a consistent unmet need in this population.
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objeCtives: Initial treatment of chronic myeloid leukemia in chronic phase (CML-CP) 
is very important and tyrosine kinase inhibitors (TKIs) are effective to delay the pro-
gression of chronic phase in accelerated and blastic phase. Dasatinib and nilotinib 
have been compared to imatinib as first line treatments for CML in two recent ran-
domised studies. However, no head to head evidence exists of the relative efficacy of 
dasatinib and nilotinib. The purpose of this study is to compare the clinical effects 
between the three targeted agents in CML patients. Methods: We conducted a sys-
tematic review and used the data extracted to perform an indirect comparison meta-
analysis of the three interventions. A random-effects approach was used to estimate 
the probability of response at each time point, and indirect comparison was imple-
mented in the WinBUGS software packages. Results: Data from nine clinical studies 
(3 trials) were included. The risk ratio of complete cytogenetic response (CCyR) and 
major molecular response (MMR) for dasatinib and nilotinib were significantly better 
than imatinib (CCyR and MMR at 6 months: 1.24 to 1.49 and 2.75 to 3.35; CCyR and 
MMR at 12 months: 1.18 to 1.23 and 1.50 to 1.99). A result of comparing the three TKIs 
of CCyR or MMR at 12 and 24 months’ follow-up through Bayesian indirect comparison 
nilotinib is the treatment showed a better response than the dasatinib (dasatinib vs. 
nilotinib at 24 months CCyR (95%CrI): 0.798 (0.300-0.986) vs. 0.844 (0.382-0.990); dasat-
inib vs. nilotinib at 24 months MMR (95%CrI): 0.604 (0.112-0.955) vs. 0.683 (0.173-0.970)).
The overall survival and progression-free survival were not significantly different 
compared to the imatinib. ConClusions: On the basis of a systematic review of 
the current literature base, dasatinib and nilotinib should be viewed as dominant 
compared to imatinib. However, further clinical studies directly comparing nilotinib 
and dasatinib are required for more accurate comparisons between the three TKIs.
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